Mode
Text Size
Log in / Sign up
N/A N=10 Diagnostic

Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance

Abdominal Adhesions

Enrolled (actual)
10
Serious AEs
10.0%
Results posted
Mar 2012
Primary outcome: Primary: Completion of Diagnostic Peritineoscopy — 8 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transgastric diagnostic peritoneoscopy with laparoscopic assistance (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ethicon Endo-Surgery
Primary completion
Oct 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Completion of Diagnostic Peritineoscopy
8

Summary

The study will document being able to successfully perform transgastric diagnostic peritoneoscopy (laparoscopic visualization) using a small collection of study surgical tools.

Eligibility Criteria

Inclusion Criteria

Men and women will be enrolled in this study who:

  • Are willing to give consent and comply with evaluation and treatment schedule;
  • At least 18 years of age;
  • Are a candidate for surgical weight loss intervention (i.e. meet ASMBS and NIH criteria) for an RYGB procedure at the Investigational site;
  • Have a history of open abdominal surgery or laparoscopic abdominal surgery;
  • ASA Classification I, II, or III (Appendix II); and
  • Have a negative serum pregnancy test (for women of childbearing potential).

Exclusion Criteria

Subjects will be excluded from the study for any of the following:

  • Use of immunosuppressive medications (within 6 months of surgery; single burst dosages and inhalable steroids are acceptable);
  • Acute cholecystitis or acute pancreatitis;
  • Evidence of abdominal abscess or mass;
  • Diffuse peritonitis;
  • Use of anticoagulants or anti-platelet agents (use of daily cardio protective doses of aspirin, up to 81 mg/day, is acceptable and shall not constitute an exclusion criterion) or the presence of coagulopathy;
  • Clinical diagnosis of sepsis;
  • Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial;
  • Planned concurrent surgical procedure other than RYGB or adhesiolysis;
  • Prior or planned major surgical procedure within 30 days before or after study procedure;
  • Participation in any other investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints;
  • Previously enrolled in the current series of 4 trials investigating the EES NOTES GEN1 Toolbox; or
  • Any condition which precludes compliance with the study (Investigator discretion).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00962650). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search